Novo warns Wegovy starter-dose limits will run into 2024

Novo Nordisk told the public on August 10, 2023, that supply restrictions on the lower starting doses of Wegovy, its weekly injectable semaglutide medicine for chronic weight management, would carry into 2024.^[1] This timeline pushed back an earlier signal from the company that the shortage would ease sooner, and it left people who had not yet started treatment in a harder spot than those already on the drug.^[1]

The core problem described is straightforward: Wegovy is dosed in a step-up schedule, starting at a low amount and increasing over weeks to a maintenance dose. When the lower starter doses run short, brand-new patients cannot begin the medicine as planned, even if higher, later-stage doses are more available.^[1] The available source does not give exact production numbers, specific dose strengths affected, or a breakdown by region, so those details are not yet known from what is provided here.^[1]

The source also does not spell out why Novo Nordisk needed additional months beyond its original projection, whether the delay was tied to manufacturing capacity, ingredient supply, packaging lines, or surging demand outpacing forecasts. Any of those could plausibly play a role in a drug shortage, but confirming the specific cause for Wegovy's 2023-to-2024 extension is not possible from the material available.^[1]

Why it matters for patients

For people who have never taken Wegovy, this kind of shortage means the practical barrier to starting treatment is not just cost or insurance approval, it is whether a pharmacy can actually fill the starter dose their doctor prescribes.^[1] Patients already partway through the dose-escalation schedule may be less affected if higher doses remain more available, but someone beginning treatment fresh in late 2023 or into 2024 could face delays before they take their first dose.^[1]

This also matters for how patients and doctors plan treatment timing. If a starting dose is not available when a prescription is written, a patient may need to wait, check multiple pharmacies, or discuss timing with a prescriber, since the source does not indicate any alternative starter option being introduced during this period.^[1] The extension of the shortage into 2024, beyond what Novo Nordisk had earlier suggested, also underscores that supply guidance from manufacturers during a drug shortage can shift, and patients relying on an earlier estimate may need to adjust their expectations for how long a wait might last.^[1]

The source does not address whether Novo Nordisk offered patients or pharmacies any interim guidance, such as alternative starting strategies or communication about specific lot availability, so that information is not yet known.^[1]

What happens next

The only date given in the available material is that the restrictions were expected to run into 2024, without a specific month or quarter identified for when the lower starting doses might become more broadly available again.^[1] Because further reporting or company updates are not included in the source provided, it is not yet known what has changed since this August 2023 statement, including whether the shortage resolved on the timeline Novo Nordisk described or continued longer.^[1]